NO20045556L - Forbindelse om opphever DNA-skade indusert cellesyklus G2 checkpoint og/eller forsterker anti-cancer aktiviteten ved DNA-skadende behandlinger - Google Patents

Forbindelse om opphever DNA-skade indusert cellesyklus G2 checkpoint og/eller forsterker anti-cancer aktiviteten ved DNA-skadende behandlinger

Info

Publication number
NO20045556L
NO20045556L NO20045556A NO20045556A NO20045556L NO 20045556 L NO20045556 L NO 20045556L NO 20045556 A NO20045556 A NO 20045556A NO 20045556 A NO20045556 A NO 20045556A NO 20045556 L NO20045556 L NO 20045556L
Authority
NO
Norway
Prior art keywords
checkpoint
dna
cell cycle
compound
induced cell
Prior art date
Application number
NO20045556A
Other languages
English (en)
Inventor
Takumi Kawabe
Hidetaka Kobayashi
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Publication of NO20045556L publication Critical patent/NO20045556L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/26—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/36—Esters of dithiocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives preparater og metoder for å inhibere cellesyklus-G2-kontrollpunktet og særlig det DNA-skadeinduserte G2-kontrollpunkt, i pattedyrceller inkludert humanceller. Spesifikt tilveiebringer oppfinnelsen preparater og metoder for å sensitisere celler mot DNA-skadende midler ved å abrogere cellesyklus-G2kontrollpunktet. Forbindelsene benyttes for å behandle proliferative lidelser som cancer. Det tilveiebringes preparater og metoder for selektivt å sensitisere G1-kontrollpunktforringede cancerceller mot DNA-skadende midler og behandlinger.
NO20045556A 2002-06-06 2004-12-20 Forbindelse om opphever DNA-skade indusert cellesyklus G2 checkpoint og/eller forsterker anti-cancer aktiviteten ved DNA-skadende behandlinger NO20045556L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38693002P 2002-06-06 2002-06-06
PCT/IB2003/003164 WO2003104181A2 (en) 2002-06-06 2003-06-06 Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments

Publications (1)

Publication Number Publication Date
NO20045556L true NO20045556L (no) 2005-03-04

Family

ID=29736236

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045556A NO20045556L (no) 2002-06-06 2004-12-20 Forbindelse om opphever DNA-skade indusert cellesyklus G2 checkpoint og/eller forsterker anti-cancer aktiviteten ved DNA-skadende behandlinger

Country Status (13)

Country Link
US (4) US7030111B2 (no)
EP (1) EP1511713B8 (no)
JP (2) JP4919598B2 (no)
KR (1) KR100984951B1 (no)
CN (1) CN100577631C (no)
AT (1) ATE520653T1 (no)
AU (1) AU2003247044B8 (no)
CA (1) CA2487388C (no)
ES (1) ES2369534T3 (no)
IL (2) IL165323A0 (no)
NO (1) NO20045556L (no)
WO (1) WO2003104181A2 (no)
ZA (1) ZA200409650B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL165323A0 (en) * 2002-06-06 2006-01-15 Canbas Co Ltd Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2005014856A1 (en) * 2003-08-08 2005-02-17 Canbas Co., Ltd. Sensitivity test to predict efficacy of anti-cancer therapies
WO2007097010A1 (ja) * 2006-02-21 2007-08-30 The Kitasato Institute Ｆｋｉ−２３４２物質およびその製造法
EP2081565A2 (en) * 2006-10-13 2009-07-29 Reliance Life Sciences Pvt., Ltd. Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
DK3567035T3 (da) * 2007-04-11 2022-09-05 Canbas Co Ltd N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
EP3578974A1 (en) * 2018-06-08 2019-12-11 Novagray Bleomycin for mimicking the effect of ionizing radiations on t cells

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913483A (en) * 1958-05-08 1959-11-17 Dow Chemical Co Lower alkylphenyl 2, 4-dichloro-benzoates
DE2049865A1 (en) * 1970-10-10 1972-04-13 Dynamit Nobel Ag, 5210 Troisdorf Aromatic acid aryl esters - prepd from aromatic trichloromethyl cpds phenols and water
US4394389A (en) * 1979-03-01 1983-07-19 Riet Bartholomeus Van T Hydroxybenzohydroxamic acids, benzamides and esters as ribonucleotide reductase inhibitors
JPS56110777A (en) * 1980-02-07 1981-09-02 Chisso Corp Ester derivative of 4-fluorobenzoic acid
US4612386A (en) * 1980-09-16 1986-09-16 The Dow Chemical Company Process for making esters
JPS58188838A (ja) * 1982-04-27 1983-11-04 Chisso Corp ４−（４′−フルオロベンゾイルオキシ）フエノ−ルのエステル誘導体
US4934389A (en) * 1988-12-06 1990-06-19 Pettiford William L Dental floss dispenser
FR2649977B1 (fr) * 1989-07-18 1991-10-04 Cird Esters bi-aromatiques, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
JP2696434B2 (ja) * 1991-01-23 1998-01-14 富士写真フイルム株式会社 画像形成方法
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US6017958A (en) 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
CA2216559A1 (en) * 1997-09-25 1999-03-25 Michel Roberge G2 checkpoint inhibitors and assay
EP1070068B2 (en) * 1998-03-13 2007-01-17 The University Of British Columbia Granulatimide derivatives for use in cancer treatment
WO1999048495A1 (en) * 1998-03-25 1999-09-30 Biosource Technologies, Inc. Benzoates derivatives for inhibiting angiogenesis
ES2239037T3 (es) 1999-09-22 2005-09-16 Canbas Co., Ltd. Metodos y composiciones para inhibir la deteccion del ciclo celular en g2 y sensibilizar celulas a agentes dañinos del dna.
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
PT1483290E (pt) * 2002-01-17 2008-09-19 Takeda Pharmaceutical Peptídeos e peptidomiméticos possuindo actividade antiproliferativa e/ou que aumentam os agentes ou tratamentos de danificação dos ácidos nucleicos
WO2003101444A1 (en) * 2002-05-29 2003-12-11 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
IL165323A0 (en) * 2002-06-06 2006-01-15 Canbas Co Ltd Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
US6881573B2 (en) * 2003-09-12 2005-04-19 Allan L. Louderback Augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses

Also Published As

Publication number Publication date
JP2010168398A (ja) 2010-08-05
CA2487388C (en) 2011-05-10
US7629364B2 (en) 2009-12-08
KR100984951B1 (ko) 2010-10-01
US7652042B2 (en) 2010-01-26
WO2003104181A3 (en) 2004-07-29
US20080293137A1 (en) 2008-11-27
KR20050019730A (ko) 2005-03-03
US20060122269A1 (en) 2006-06-08
ZA200409650B (en) 2006-09-27
WO2003104181A2 (en) 2003-12-18
IL165323A0 (en) 2006-01-15
ES2369534T3 (es) 2011-12-01
US20040198727A1 (en) 2004-10-07
JP4919598B2 (ja) 2012-04-18
EP1511713B1 (en) 2011-08-17
CN100577631C (zh) 2010-01-06
IL165323A (en) 2015-05-31
AU2003247044B8 (en) 2009-04-09
US7030111B2 (en) 2006-04-18
CA2487388A1 (en) 2003-12-18
EP1511713A2 (en) 2005-03-09
AU2003247044B2 (en) 2009-03-26
EP1511713B8 (en) 2012-02-08
ATE520653T1 (de) 2011-09-15
JP2005528457A (ja) 2005-09-22
US7407985B2 (en) 2008-08-05
CN1671644A (zh) 2005-09-21
US20080227827A1 (en) 2008-09-18
AU2003247044A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
NO20033858D0 (no) Aryl- og heteroarylurea-CHK1-inhibitorer for anvendelse som radiosensitiviseringsmidler og chamosensitiviseringsmidler
CY1110084T1 (el) Χρηση συμπυκνωμενων ετεροκυκλικων ενωσεων ως αναστολεις scce για την θεραπευτικη αγωγη δερματικων ασθενειων
BR112012010762A2 (pt) inibidores de prolil hidroxilalse
MX2009011025A (es) Compuestos con actividad anticancer.
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
NO20081349L (no) Pyrrolopyrimidinderivater som Syk-inhibitorer
NO20061194L (no) Mitotiske kinesininbibitorer
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
WO2005030121A3 (en) Compounds, compositions and methods
NO20070067L (no) Pyrrolopyridinderivater
NO20074944L (no) Heteroarylureaderivater anvendlige for inhibering av CHK1
NO20073574L (no) Triazolsubstituerte aminobenzofenonforbindelser
DE10393306D2 (de) Mesenchymale Stammzellen des Haarfollikels und deren Verwendung
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
PT1218494E (pt) Composicoes e metodos para inibir a paragem do ciclo celular g2 e para sensibilizar celulas perante agentes que danificam o adn
WO2006021002A3 (en) Compounds useful for inhibiting chk1
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
NO20045556L (no) Forbindelse om opphever DNA-skade indusert cellesyklus G2 checkpoint og/eller forsterker anti-cancer aktiviteten ved DNA-skadende behandlinger
DE60135482D1 (de) Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen
NO20081195L (no) Imidazopyridinderivater som kannabinoidreceptorligander
CY1114825T1 (el) Συνθεσεις και μεθοδοι αγωγης διαταραχων υπερπλασιας κυτταρων